close

XenoPort, Inc., a biopharmaceutical company, focuses on developing internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to enhance the therapeutic benefits of drugs. Its portfolio of product candidates includes XP13512, which is a transported prodrug of gabapentin, has been evaluated in a phase III clinical program for the treatment of restless legs syndrome, as well as completed a phase IIa clinical trial for the management of post-herpetic neuralgia; XP19986, a transported prodrug of R-baclofen for the treatment of gastroesophageal reflux disease and spasticity; and XP21279, a transported prodrug of levodopa, which is in phase I clinical trial for the treatment of Parkinson's disease. The company also develops XP21279, a transported prodrug of L-Dopa, for the treatment of Parkinson's disease; and XP21510, a transported prodrug of tranexamic acid, for the treatment of menorrhagia or heavy menstrual bleeding. XenoPort has strategic alliances with Astellas Pharma, Inc.; Glaxo Group Limited; and Xanodyne Pharmaceuticals, Inc. The company was founded in 1999 and is based in Santa Clara, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	3.99
Volume	148881
Volume Avg	198148
52 Week High	11.34
52 Week Low	3.46
PE	N/A
PE (group average)	39
EPS Year	-0.94
EPS change Q/Q	-4.26%
EPS change Q/Q Yr ago	-47.31%
EPS change Q/Q next Q est	-28.95%
EPS change Y/Y	-37.78%
REV change Q/Q	-78.95%
REV change Q/Q Yr ago	300%
EPS next Q est	-0.38
EPS next Y est	-1.15
Divident Annual	0.00
Dividend Yield	0%